Best of Ophthalmology Research
Author(s)/Faculty: Rishi P. Singh, MD; Sunil S. Patel, MD, PhD; Charles C. Wykoff, MD, PhD
Expiration Date: 5/10/2019
Provider: Vindico Medical Health
Source: Retina CME
Number of Credits: 0.75
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of persons with neovascular retinal disease. Unfortunately, some patients do not receive benefit from anti-VEGF therapy or receive only suboptimal benefit, defining a need for novel targeted therapies. Novel agents that target pathways contributing to abnormal angiogenesis and increased vascular permeability are currently being assessed in clinical studies, with several of these promising therapies targeting the Tie2 signaling pathway. As these novel targeted therapies progress through clinical studies, it is imperative that health care professionals caring for patients with neovascular retinal disease are kept informed about treatment advances. In this CME activity, recorded during the summer meeting in Honolulu, experts in the field review the need for alternatives to anti-VEGF monotherapy for neovascular disease, discuss pathways that contribute to abnormal angiogenesis and increased vascular permeability, as well as evaluate the most recent efficacy and safety data for investigational agents that target the Tie2 pathway in retinal disease.
Direct Link: Retina CME